Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GRAIL, Inc.
Age
50–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Cohort A: Elevated Risk Group (70% of cohort):
Age: Participant must be 50 years of age or older at the time of signing the Informed Consent Form (ICF).
Participants must meet at least one of the criteria below:
History of smoking at least 100 cigarettes in his or her lifetime
Documented genetic cancer predisposition, hereditary cancer syndrome, or meeting criteria for germline testing based on current NCCN guidelines
Personal history of invasive or hematologic malignancy, with definitive treatment completed greater than 3 years prior to enrollment. Adjuvant hormone therapy for cancer is permissible (ie may be ongoing within 3 years or at the time of enrollment).
Cohort B: Non-Elevated Risk Group (30% of cohort):
Age: Participant must be 50 years of age or older, at the time of signing the Informed Consent Form (ICF).
None of the conditions described in Cohort A, criteria 2a-c
For all participants, capable of giving signed and legally effective informed consent
You may not be if
Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
Personal history of invasive or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated.
Definitive treatment for invasive or hematologic malignancy within the 3 years prior to expected enrollment date. Adjuvant hormone therapy for cancer is not an exclusion criterion.
Individuals who will not be able to comply with the protocol procedures.
Individuals who are not current patients at a participating center.
Previous or current participation in another GRAIL-sponsored study.
Previous or current employees or contractors of GRAIL.
Clareo Health | Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
